Drugs / Emtricitabine/tenofovir disoproxil
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07071623 Comparator | Nov 2025 → Oct 2027 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine/tenofovir disoproxil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07071623 ↗ |
| Known as | FTC/TDF | “Emtricitabine/tenofovir disoproxil (FTC/TDF)” NCT07071623 ↗ |
| Route | Oral | “Oral tablet” NCT07071623 ↗ |